Browsing by Author "Aventis Pasteur"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
    (2005-03-31) Chitraporn Karnasuta; Robert M. Paris; Josephine H. Cox; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Arthur E. Brown; Sanjay Gurunathan; James Tartaglia; William L. Heyward; John G. McNeil; Deborah L. Birx; Mark S. De Souza; Armed Forces Research Institute of Medical Sciences, Thailand; U.S. Military HIV Research Program; Mahidol University; Sanofi Pasteur SA; Aventis Pasteur; VaxGen, Inc.
    Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX® B/E gp120 prime-boost vaccine trial in Thailand. ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients. There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients. The frequency of responders to subtype B and to CRF01_AE was 96% and 84% in the vaccine group versus 11% and 7% in the placebo group. The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.